U.S. market Closed. Opens in 1 hour 50 minutes

SNN | Smith & Nephew plc Stock Overview

(Stock Exchange: NYSE)
Day's Range 25.02 - 25.24
52 Week Range 23.65 - 31.72
Beta 0.87
Implied Volatility 48.94%
IV Rank 53.86%
Day's Volume 614,367
Average Volume 781,995
Shares Outstanding 435,987,000
Market Cap 10,991,232,270
Sector Healthcare
Industry Medical - Devices
IPO Date 1999-11-16
Valuation
Profitability
Growth
Health
P/E Ratio 36.01
Forward P/E Ratio N/A
EPS 0.70
1YR Price Target N/A
Dividend Yield 2.26%
Dividend Per Share 0.57
Dividend ExDate N/A
Dividend PayDate N/A
Employees 18,000
Country UK
Website SNN
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
*Chart delayed
Analyzing fundamentals for SNN we got that it has weak fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is very bad and Health is passable. For more detailed analysis please see SNN Fundamentals page.

Watching at SNN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SNN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙